SCHEMBL2329635

SCHEMBL2329635

COP(=O)(CC(=O)c1ccc(Cl)cc1C)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 4/20 0.40
CYP11B2 P19099 1/20 0.40
TSHR P16473 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ABL1 P00519 1/20 0.40
MAPT P10636 3/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322156 0.86 ALDH1A1 (0.56) FLT1FLT4KDRCYP1A2CYP2D6
SCHEMBL2322299 0.84 TAS1R3 (0.46) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL2324762 0.83 ALDH1A1 (0.50) FLT1FLT4KDRCYP1A2CYP2C19
SCHEMBL2325145 0.82 HTT (0.39) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL9257364 0.79 LMNA (0.50) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL2329637 0.78 TDP1 (0.43) FLT1FLT4KDRCYP1A2CYP2D6
SCHEMBL1549242 0.78 ERCC5 (0.49) ALDH1A1TSHRRAB9ANPC1SMN1; SMN2
SCHEMBL1549850 0.77 HTT (0.46) CYP1A2CYP2D6CYP2C19RAB9ASMN1; SMN2
SCHEMBL27776199 0.76 FLT1 (0.43) FLT1FLT4KDRCYP1A2CYP2D6
SCHEMBL5733465 0.75 SUCNR1 (0.51) CYP1A2CYP2D6CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 FLT1 2089/4885FLT4 3773/4885KDR 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.